New drug Kylo-11 tested to lower hidden heart risk
NCT ID NCT06363851
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called Kylo-11 in 71 healthy adults with high levels of Lp(a), a genetic risk factor for heart disease. The main goal was to check safety and how the drug moves through the body. Researchers gave single doses at different levels to see if it's safe and well-tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Kylo-11
- What this could lead to
- If successful, this could lead to a new treatment to lower Lp(a) and reduce heart disease risk.
- What could go wrong
- This is a very early, small study in healthy volunteers, not patients. It only tests safety and dosing, not whether it actually prevents heart problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chengdu Xinhua Hospital
Chengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can better healthcare access save hearts after prison?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Could a simple health chat slash heart disease and cancer risk?
- One scan, many answers: can a new CT predict heart risks after stenting?
- Digital coaching aims to boost heart health in obesity
- Can a new device suck out deadly lung clots?